Arotinolol
From Wikipedia, the free encyclopedia
![]() |
|
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Oral (tablets) |
ATC code | none |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 2 hours |
Biological half-life | 10 hours |
Identifiers | |
|
|
CAS Number | 41287-43-8 ![]() |
PubChem (CID) | 2239 |
ChemSpider | 2152 ![]() |
UNII | 394E3P3B99 ![]() |
KEGG | D07465 ![]() |
ChEMBL | CHEMBL93298 ![]() |
Chemical and physical data | |
Formula | C15H21N3O2S3 |
Molar mass | 371.54 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
![]() ![]() |
Arotinolol (INN, marketed under the tradename Almarl) is a medication in the class of mixed alpha/beta blockers.[1] It also acts as a β3 receptor agonist.[2] A 1979 publication suggests arotinolol as having first been described in the scientific literature by Sumitomo Chemical as "β-adrenergic blocking, antiarrhythmic compound S-596".[3]
Uses[edit]
It is used in the treatment of high blood pressure[4] and essential tremor.[5][6]
Recommended dosage is 10–30 mg per day.
References[edit]
- ^ Zhao, Jin; Golozoubova, Valeria; Cannon, Barbara; Nedergaard, Jan (July 2001). "Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes". Can J Physiol Pharmacol. 79 (7): 585–593. doi:10.1139/cjpp-79-7-585. PMID 11478592.
- ^ Takahashi, H; Yoshida, T; Nishimura, M; Nakanishi, T; Kondo, M; Yoshimura, M (September 1992). "Beta-3 Adrenergic Agonist, BRL-26830A, and Alpha/Beta Blocker, Arotinolol, Markedly Increase Regional Blood Flow in the Brown Adipose Tissue in Anesthetized Rats". Japanese Circulation Journal. 56 (9): 936–42. doi:10.1253/jcj.56.936. PMID 1383578.
- ^ Hara, Youichi; Sato, Etsuro; Miyagishi, Akira; Aono, Shunzi; Nakatani, Hiroshi (1979). "新しいβ-受容体遮断薬,dl-2-(3'-t-Butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)-thiazole hydrochloride (S-596) の薬理作用" [Pharmacological properties of dl-2-(3'-t-butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole hydrochloride (S-596), a new β-adrenergic blocking agent]. Folia Pharmacologica Japonica (English abstract) (in Japanese): 707–720. doi:10.1254/fpj.75.707. ISSN 1347-8397.
- ^ Wu, Haiying; Zhang, Yuqing; Huang, Jianfeng; Zhang, Yuhui; Liu, Guozhang; Sun, Ningling; Yu, Zhenqui; Zhou, Yanrong (September 2001). "Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers" (PDF). Hypertension Research. 24 (5): 605–10. doi:10.1291/hypres.24.605. ISSN 1348-4214. PMID 11675958.
- ^ Lee, Kwang-Soo; Kim, Joong-Seok; Kim, Jae-Woo; Lee, Won-Yong; Jeon, Beum-Seok; Kim, Dongjae (August 2003). "A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor" (PDF). Parkinsonism & Related Disorders. 9 (6): 341–347. doi:10.1016/S1353-8020(03)00029-4. PMID 12853233.
- ^ "Almarl (アルマール) Arotinolol HCl Tablets. Full Prescribing Information" (PDF). Sumitomo Dainippon Pharma Co., Ltd. Retrieved 6 March 2016.
External links[edit]
- (Japanese) Almarl Full Prescribing Information. Revised November 2009 Sumitomo Dainippon Pharma Co., Ltd.
- (Japanese) Official Sumitomo Dainippon Pharma Website
- https://web.archive.org/web/20110722132720/http://sdic.sookmyung.ac.kr/drug_monograph/view.asp?id=92
![]() |
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
![]() |
This article about an amine is a stub. You can help Wikipedia by expanding it. |